Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

741,547 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 74,155
1.WO/2024/096877BETA-GLUCAN TREATMENT TO PROMOTE AXON REGENERATION
WO - 10.05.2024
Int.Class A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
 Appl.No PCT/US2022/048719 Applicant BIOTHERA, INC. DBA IMMUNO RESEARCH INC. Inventor KAREL, Steven
Intra-ocular injection of polymeric β(1,3; 1,6)-glucan (β-glucan) triggers a strong immune response in the eye. When combined with retro-orbital optic nerve crush injury (ONC), β-glucan promotes lengthy regeneration of severed retinal ganglion cell (RGC) axons.
2.WO/2024/097897LXR MODULATORS WITH BICYCLIC CORE MOIETY FOR TREATING DYSLIPIDEMIAS
WO - 10.05.2024
Int.Class A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
 Appl.No PCT/US2023/078547 Applicant ORSOBIO, INC. Inventor VIJAYAKUMAR, Archana
The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/or treatment of diseases which are associated with the modulation of LXR, for example, dyslipidemias. The present disclosure further relates to the use of the present compounds in the prophylaxis and/or treatment of metabolic disorders associated with an impairment in lipid homeostasis.
3.WO/2024/097972COMPOUNDS AND METHODS FOR TREATING CANCERS
WO - 10.05.2024
Int.Class C07D 487/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
12in which the condensed system contains three hetero rings
14Ortho-condensed systems
 Appl.No PCT/US2023/078657 Applicant CEDARS-SINAI MEDICAL CENTER Inventor LU, Shelly
The present invention describes compounds that inhbits GIT1. The invention further describes compositions containing these GIT1 inhibitors, as well as methods and kits using these GIT1 inhbitors to treat various medical conditions. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.
4.WO/2024/095137PHARMACEUTICAL COMPOSITION OF EMPAGLIFLOZIN AND PROCESS THEREOF
WO - 10.05.2024
Int.Class A61K 31/7048
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7048having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
 Appl.No PCT/IB2023/060936 Applicant MOREPEN LABORATORIES LIMITED Inventor CHATURVEDI, Kiran
The present invention relates to a stable pharmaceutical composition of empagliflozin or its pharmaceutically acceptable salts, solvates thereof along with one or more pharmaceutically acceptable excipients. More specifically, the present invention relates to a process of preparing a stable pharmaceutical composition of empagliflozin.
5.WO/2024/093907LIGAND FOR DELIVERING SIRNA TO EYE AND CENTRAL NERVOUS SYSTEM
WO - 10.05.2024
Int.Class C07D 265/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
265Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
281,4-Oxazines; Hydrogenated 1,4-oxazines
30not condensed with other rings
 Appl.No PCT/CN2023/127728 Applicant SHANGHAI RONA THERAPEUTICS CO., LTD. Inventor HUANG, Jinyu
Provided are a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The compound of formula (I) is contained inside a nucleotide, or at a 5' end and/or a 3' end, and is used for improving the ability of a double-stranded RNA to pass through the blood-brain barrier. The present invention further relates to a test kit, a pharmaceutical composition, a cell, a carrier, a double-stranded RNA, or an oligonucleotide comprising the compound of formula (I).
6.WO/2024/092407PIPERACILLIN AND TAZOBACTAM SPRAY-DRIED POWDER
WO - 10.05.2024
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
 Appl.No PCT/CN2022/128625 Applicant CURACO BIOPHARM (NANJING) CO., LTD. Inventor SIM, Kim Eng
Piperacillin and tazobactam spray-dried powder, which is powdered spherical particles prepared by means of a spray drying method, and comprises piperacillin or a pharmaceutically acceptable salt thereof and tazobactam or a pharmaceutically acceptable salt thereof, and further comprises one or more stabilizers selected from carbohydrates, amino acids and polyols. A piperacillin and tazobactam formulation prepared by means of a spray drying method.
7.WO/2024/093412HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO - 10.05.2024
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
 Appl.No PCT/CN2023/111120 Applicant GUANGDONG ZHONGKE MEDICINE RESEARCH LTD. Inventor WANG, Wei
A heterocyclic compound, a preparation method therefor, and an application thereof. The structural formula of the heterocyclic compound is as represented by formula I. The present compound has excellent bioavailability, can improve cerebral blood flow levels in an ischemia-reperfusion animal model, reduces the area of cerebral infarction, and can be used for diseases such as cerebral stroke.
8.WO/2024/095962USE OF PYRIDINE DERIVATIVE WHICH IS TRPV1 ANTAGONIST
WO - 10.05.2024
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
 Appl.No PCT/JP2023/039098 Applicant SHIONOGI & CO., LTD. Inventor YAMAKAWA, Hidekuni
The present invention provides a novel pharmaceutical composition and a method for treating and/or preventing social impairment, such as autism spectrum disorder, fragile X syndrome, and/or autism spectrum-like symptoms. Specifically, provided is a pharmaceutical composition for the treatment and/or prevention of social impairment, the pharmaceutical composition comprising a compound represented by formula (I) (in the formula, R1 is a substituted or unsubstituted alkyl; R2 is a hydrogen atom or the like; A is N or the like; the dashed line represents the presence or absence of a bond; R3 is a substituted or unsubstituted alkyl or the like; m is 0 or 1; and R4 and R5 each independently represent a hydrogen atom or the like) or a pharmaceutically acceptable complex thereof.
9.WO/2024/095992IMPROVEMENT OF RENAL HYPOFUNCTION BY SUBSTANCE HAVING AMMONIA EXCRETION-PROMOTING EFFECT
WO - 10.05.2024
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No PCT/JP2023/039194 Applicant TAZ INC. Inventor KAMIMOTO TAKAHASHI Shoko
The present invention addresses the problem of providing a novel means for suppressing renal hypofunction, the means being capable of fundamentally improving diseases associated with renal hypofunction, including chronic kidney disease (CKD).　The present inventors solved the aforesaid problem by providing a novel means for suppressing renal hypofunction, the means suppressing and/or improving renal hypofunction in a living body using a substance having ammonia excretion-promoting effect. More specifically, the present invention solved the aforesaid problem by providing a renal hypofunction suppressing agent that contains a substance having ammonia excretion-promoting effect in a living body.
10.WO/2024/097387COMPOSITIONS FOR INTRAVENOUS ADMINISTRATION
WO - 10.05.2024
Int.Class A61K 9/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
 Appl.No PCT/US2023/036747 Applicant ASTROCYTE PHARMACEUTICALS, INC. Inventor POE, Russell Birch
The present invention provides compounds, compositions, and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
# -